Muscle Disease and Myasthenia Gravis Flashcards

1
Q

Definition - Myasthenia Gravis.

A

Autoimmune condition that causes muscle weakness that gets progressively worse with activity and improves with rest.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Association - Thymomas and Myasthenia Gravis

A

10-20% of patients with Myasthenia Gravis have a Thymoma (or 50-70% - thymic hyperplasia).
20-40% of patients with a Thymoma develop Myasthenia Gravis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Myasthenia Gravis vs. Lambert-Eaton Myasthenic Syndrome (5).

A
  1. Definition : MG & LEMS - Progressive muscle weakness as a result of damage at the NMJ.
  2. Course : MG - More insidious and less pronounced symptoms.
  3. Association : MG - Thymoma. LEMS - SCLC.
  4. Antibodies : MG - Anti-ChR, Anti-MuSK, Anti-LPR4. LEMS - Anti-VGCC (in presynaptic terminals of NMJ).
  5. Muscle Weakness : MG - Facial and Ocular Muscles. LEMS - Proximal Limb Weakness (Legs > Arms).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is Post-Tetanic Potentiation?

A

Reflexes become temporarily normal for a short period following a period of strong muscle contraction but are otherwise reduced.

This is a feature of LEMS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Epidemiology of Myasthenia Gravis (3).

A
  1. Men : >60.
  2. Women : <40.
  3. 2x Women : Men.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Clinical Features of Myasthenia Gravis (5).

A
  1. Weakness worsens with activity and improves with rest (minimal in morning and worse at the end of the day).
  2. Proximal Muscles and Small Muscles of Head and Neck.
  3. Diplopia (Extraocular - Double Vision).
  4. Ptosis (Eyelid - Drooping).
  5. Weakness in Facial Movements, Swallowing, Chewing, Slurred Speech.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Pathophysiology of Myasthenia Gravis.

A

85% : Anti-AChR antibodies bind to post-synaptic receptors at NMJ to prevent ACh functioning. As the receptors are used more during muscle activity, most of them will become blocked up, leading to less effective stimulation of the muscle with increased activity. Antibodies also activate the Complement at the NMJ to damage post-synaptic membrane cells.
15% : Anti-MuSK (Muscle Specific Kinase) or Anti-LRP4 (Low-Density Lipoprotein Receptor-Related Protein 4).
MuSK and LRP4 are responsible for the creation and organisation of the AChR.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Examination of Myasthenia Gravis (3C).

A
  1. Thymectomy Scar.
  2. FVC.
  3. Fatiguability
    A. Repeated Blinking - Ptosis Exacerbation.
    B. Prolonged Upward Gazing - Diplopia Exacerbation.
    C. Repeated Abduction of One Arm 20x - Weakness Exacerbation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Investigations of Myasthenia Gravis.

A
  1. Bloods - CK is not raised (no muscle damage).
  2. CT Thorax - exclude Thymoma.
  3. Single Fibre Electromyography (high sensitivity).
  4. Bloods - Measure Antibodies (Anti-AChR; Anti-MuSK; Anti-LRP4).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Single Fibre Electromyography.

A

Needles are inserted into the muscles to measure electrical activity - typically around the eyes, forehead, arms. Electrical recordings can show whether signals sent to muscles from nerves are being disrupted.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tensilon/Edrophonium Test.

A

Patients are given an IV dose of Edrophonium Chloride/Neostigmine. Usually, AChEs in the NMJ break down Ach. Edrophonium blocks AchEs at the NMJ so ACh levels rise, giving a brief and temporary relief of muscle weakness.

This is no longer use due to the risk of cardiac arrhythmias.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Treatment Options in Myasthenia Gravis (4).

A
  1. Reversible AChE Inhibitors e.g. Pyridostigmine, Neostigmine.
  2. Immunosuppression e.g. Prednisolone, Azathioprine, Cyclosporine, Mycophenolate Mofetil.
  3. Thymectomy.
  4. Monoclonal Antibodies.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Reversible Acetylcholinesterase Inhibitors - Adverse Effects (7).

A
  1. Hypersalivation.
  2. Lacrimation.
  3. Sweats.
  4. Vomiting.
  5. Miosis.
  6. Diarrhoea.
  7. Colic.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Monoclonal Antibodies - Mechanism of Action (2).

A
  1. Rituximab - targets B cells to reduce the production of antibodies (NHS if standard treatment is not effective).
  2. Eculizumab - targets C5 Complement Protein to prevent Complement activation and destruction of AChR (NICE do not currently recommend it).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Definition of Myasthenic Crisis.

A

A severe life-threatening complication : acute worsening of symptoms triggered by another illness e.g. RTI - leads to respiratory failure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Management of MyastheniC Crisis.

A
  1. Immunomodulatory Therapy e.g. IVIG, Plasma Exchange.

2. NIV - BiPAP, Full Intubation and Ventilation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Exacerbating Factors of Myasthenia Gravis (5).

A
  1. Exertion.
  2. Drugs (10) - Penicillamine, Quinidine, Procainamide, B-Blockers, Lithium, Phenytoin, Antibiotics : Gentamicin, Macrolidies, Quinolones, Tetracyclines.
  3. Pregnancy.
  4. Hypokalaemia.
  5. Emotion - Stress.
18
Q

Definition of Muscular Dystrophy and Types (7).

A

An umbrella term for genetic conditions that cause gradual weakening and wasting of muscles.

  1. Duchennes’.
  2. Beckers’.
  3. Myotonic.
  4. Facioscapulohumeral.
  5. Oculopharyngeal.
  6. Limb-Girdle.
  7. Emery-Dreifuss.
19
Q

Genetics of Muscular Dystrophy.

A

Boys have a single copy of the X chromosome and girls have two copies (a spare). Female carries don’t usually notice any symptoms.

20
Q

Aetiology of Duchennes Muscular Dystrophy (4).

A
  1. X-Linked Recessive (Xp21).
  2. Defective Gene for Dystrophin (a protein that helps hold muscles together at the cellular level).
  3. Frameshift mutation resulting in one or both of the binding sites being lost.
  4. Dystrophin is part of a large membrane-associated protein that connects the muscle membrane to actin.
21
Q

Aetiology of Beckers Muscular Dystrophy (2).

A
  1. Dystrophin gene is less severely affected so some function is maintained.
  2. Non-Frameshift insertion in the Dystrophin gene, resulting in both binding sites being preserved.
22
Q

Aetiology of Myotonic Dystrophy (3B).

A
  1. Autosomal Dominant.
  2. Trinucleotide Repeat Disorder.
    3A. DM1 - CTG repeat at the end of DMPK (Dystrophia Myotonica Protein Kinase) gene on Chromosome 19.
    3B. DM2 - Repeat expansion of ZNF9 on Chromosome 3.
23
Q

Gower’s Sign.

A
  1. Kid gets onto his/her hands and push his/her hips up and backwards to shift their weight backwards and transfer their hands to their knees.
  2. Whilst keeping their legs mostly straight, they walk their hands up their legs to get their upper body erect.
    * It is a compensatory movement against the muscles around the weak pelvic girdle used by kids with proximal muscle weakness to stand up from a lying position.
24
Q

Clinical Presentation of Duchennes Muscular Dystrophy.

  • Epidemiology (1).
  • Clinical Features (3).
A

Epidemiology : Boys - 3-5.
Clinical Features :
1. Weakness in Pelvic Muscles - progressive, affecting all muscles (wheelchair bound by teenages).
2. Calf-Pseudohypertrophy (Gower’s Sign).
3. Associated : Dilated Cardiomyopathy and Intellectual Impairment.

25
Q

Clinical Presentation of Beckers Muscular Dystrophy.

  • Epidemiology (1).
  • Clinical Features (3).
A

Epidemiology : Boys - 8-12.
Clinical Features :
1. Some patients require wheelchairs in late 20s/30s.
2. Others can walk with assistance into late adulthood.
3. Intellectual impairment is less common than in Duchennes.

26
Q

Clinical Presentation of Myotonic Dystrophy.

  • Clinical Features (9).
  • Types (2).
A

Clinical Features :

  1. Progressive Muscle Weakness.
  2. Prolonged Muscle Contractions (e.g. unable to let go, myotonic facies - haggard face).
  3. Cataracts and Bilateral Ptosis.
  4. Cardiac Arrhythmias.
  5. Frontal Balding.
  6. Dysarthria.
  7. Myotonia (Tonic Spasm of Muscle).
  8. Diabetes Mellitus.
  9. Testicular Atrophy.

Types :
DM1 - Distal Weakness is more prominent.
DM2 - Proximal Weakness is more prominent.

27
Q

Clinical Presentation of Facioscapulohumeral Dystrophy.

- Clinical Features (2).

A
  1. Weakness around face, progressing to shoulders and arms.
  2. Classic Initial Symptom : Sleeping with eyes slightly open and weakness in pursing lips and unable to blow cheeks out without air leaking.
28
Q

Clinical Presentation of Oculopharyngeal Dystrophy.

- Clinical Features (3).

A
  1. Weakness of Ocular Muscles and Pharyngeal Muscles.
  2. Bilateral Ptosis, Restricted Movement, Swallowing Problems.
  3. Late Adulthood Onset.
29
Q

Clinical Presentation of Emery-Dreifuss Muscular Dystrophy.

A
  1. Contractures in childhood, elbows and ankles.

These are shortenings of muscles and tendons which restrict the range of movement in limbs.

30
Q

Management of Muscular Dystrophy (3).

A
  1. No curative treatment.
  2. Aim : Highest Quality of Life.
  3. Oral Steroids - slow progression of muscle weakness by 2 years.
31
Q

Differential Diagnoses of Myopathy.

A

Inherited - Early age of onset, with relatively longer duration of disease.
Acquired - Sudden/Sub-Acute, with a later age of onset.

32
Q

Clinical Features of Myopathy (4).

A
  1. Symmetrical Muscle Weakness (Proximal > Distal).
  2. Common Problems rising from a chair/bath.
  3. Normal Sensation and Reflexes.
  4. No Fasciculation.
33
Q

Pathophysiology of Polymyositis.

A

Inflammatory disorder causing symmetrical proximal muscle weakness - T-Cell mediated cytotoxic process directed against muscle fibres; it can be idiopathic, related to connective tissue disorders or malignancy.

34
Q

Clinical Features of Polymyositis (5).

A
  1. Proximal Muscle Weakness and Tenderness.
  2. Raynaud’s.
  3. Respiratory Muscle Weakness.
  4. Interstitial Lung Disease.
  5. Dysphagia and Dysphonia.
35
Q

Epidemiology of Polymyositis.

A

Middle-Aged. Women 3:1 Men.

36
Q

Investigations of Polymyositis (3).

A
  1. 85-95% of Patients : Elevated CK levels and other muscle enzymes e.g. LDH, Aldolase, AST, ALT.
  2. Anti-Synthetase Antibodies.
  3. Anti-Jo-1 in a specific pattern with lung involvement, Raynaud’s and Fever.
37
Q

Pathophysiology of Dermatomyositis.

A

Variant of Polymyositis where skin manifestations are prominent e.g. Purple (Heliotrope) rash on cheeks and eyelids. Malignancies associated include Ovarian, Breast and Lung Cancer (20-25%).

38
Q

Clinical Features of Dermatomyositis (6).

A

In addition to Polymyositis :

  1. Photosensitive Skin.
  2. Macular Rash over Back and Shoulder.
  3. Heliotrope (Purple) Rash in Periorbital Region.
  4. Gottron’s Papules - Roughened Red Papules on Extensor Surface of Fingers.
  5. Mechanic’s Hands - extremely dry and scaly hands with linear cracks on palmar and lateral aspects of fingers.
  6. Nail Fold Capillary Dilation.
39
Q

Investigations of Dermatomyositis.

A
  1. 80% - ANA-positive.
  2. 30% - Anti-Synthetase Antibodies (Antibodies against Aminoacyl-tRNA-Synthetases) e.g. Anti-Jo-1 (Histidine-tRNA-Ligase), Anti-SRP (Signal Recognition Particles), Anti-Mi2.
40
Q

Management of Polymyositis and Dermatomyositis (2).

A
  1. Steroids (reduce swelling and ease muscle pain).

2. DMARDs - flare-up.

41
Q

Pharmacological Risk Factor for Myopathy.

A

Statins - especially lipophilic ones e.g. Simvastatin and Atorvastatin.

42
Q

Gold-Standard Investigation of Muscular Dystrophy.

A

Muscle Biopsy.